LGALS3 and pulmonary fibrosis: A phase 2 clinical study is also ongoing in patients with idiopathic pulmonary fibrosis in order to evaluate the efficacy, pharmacokinetics, and pharmacodynamics of another Gal-3 inhibitor, GB0139, previously known as TD139, inhaled in the form of dry powder [152].